CeriBell, Inc./$CBLL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CeriBell, Inc.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
Ticker
$CBLL
Sector
Primary listing
Employees
281
Headquarters
Website
CeriBell, Inc. Metrics
BasicAdvanced
$474M
-
-$1.81
-
-
Price and volume
Market cap
$474M
52-week high
$25.37
52-week low
$10.01
Average daily volume
274K
Financial strength
Current ratio
13.307
Quick ratio
12.638
Long term debt to equity
11.854
Total debt to equity
12.52
Interest coverage (TTM)
-26.29%
Profitability
EBITDA (TTM)
-50.714
Gross margin (TTM)
87.75%
Net profit margin (TTM)
-63.83%
Operating margin (TTM)
-67.14%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-24.91%
Return on equity (TTM)
-51.39%
Valuation
Price to revenue (TTM)
4.553
Price to book
2.75
Price to tangible book (TTM)
2.75
Price to free cash flow (TTM)
-9.211
Free cash flow yield (TTM)
-10.86%
Free cash flow per share (TTM)
-1.405
Growth
Revenue change (TTM)
42.17%
Earnings per share change (TTM)
-69.92%
Bulls say / Bears say
CeriBell achieved Q2 2025 revenue of $21.2 million, up 38% year-over-year, driven by strong adoption of its portable EEG platform across new and existing hospital accounts. (Nasdaq)
The company maintained a robust gross margin of 88% in Q2 2025, up from 86% a year earlier, reflecting efficient cost management and scalability of its AI-powered EEG system. (Nasdaq)
The FDA granted 510(k) clearance for Ceribell’s Clarity™ algorithm for detecting electrographic seizures in pediatric patients aged 1 and older, expanding its addressable market as the only AI-powered EEG solution cleared across the full age spectrum. (GlobeNewswire)
CeriBell’s net loss widened to $13.6 million in Q2 2025, compared to $8.9 million in the same quarter of 2024, reflecting persistent unprofitability despite revenue growth. (Nasdaq)
Operating expenses surged 56% year-over-year to $33.6 million in Q2 2025, outpacing the 38% increase in revenue and indicating ongoing pressure on cash burn and profitability. (Nasdaq)
With only 584 active hospital accounts at the end of Q2 2025, CeriBell still represents a small fraction of the estimated U.S. acute EEG market, highlighting significant adoption challenges ahead. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CeriBell, Inc. stock?
CeriBell, Inc. (CBLL) has a market cap of $474M as of October 25, 2025.
What is the P/E ratio for CeriBell, Inc. stock?
The price to earnings (P/E) ratio for CeriBell, Inc. (CBLL) stock is 0 as of October 25, 2025.
Does CeriBell, Inc. stock pay dividends?
No, CeriBell, Inc. (CBLL) stock does not pay dividends to its shareholders as of October 25, 2025.
When is the next CeriBell, Inc. dividend payment date?
CeriBell, Inc. (CBLL) stock does not pay dividends to its shareholders.
What is the beta indicator for CeriBell, Inc.?
CeriBell, Inc. (CBLL) does not currently have a Beta indicator.